Toggle Main Menu Toggle Search

Open Access padlockePrints

A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib

Lookup NU author(s): Professor Stephen O'Brien


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


In chronic-phase chronic myeloid leukemia (CML) patients, the lack of a major cytogenetic response (< 36% Ph+ metaphases) to imatinib within 12 months indicates failure and mandates a change of therapy. To identify biomarkers predictive of imatinib failure, we performed gene expression array profiling of CD34+ cells from 2 independent cohorts of imatinib-naive chronic-phase CML patients. The learning set consisted of retrospectively selected patients with a complete cytogenetic response or more than65%Ph + metaphases within 12 months of imatinib therapy.Basedonanalysis of varianceP less than .1 and fold difference 1.5 or more, we identified 885 probe sets with differential expression between responders and nonre-sponders, from which we extracted a 75-probe set minimal signature (classifier) that separated the 2 groups. On application to a prospectively accrued validation set, the classifier correctly predicted 88% of responders and83% of nonresponders. Bioinformatics analysis and comparison with published studies revealed overlap of classifier genes withCMLprogression signatures and implicated β-catenin in their regulation, suggesting that chronic-phase CML patients destined to fail imatinib have more advanced disease than evident by morphologic criteria. Our classifier may allow directing more aggressive therapy upfront to the patients most likely to benefit while sparing good-risk patients from unnecessary toxicity. © 2010 by The American Society of Hematology.

Publication metadata

Author(s): McWeeney S, Pemberton L, Loriaux M, Vartanian K, Willis S, Yochum G, Wilmot B, Turpaz Y, Pillai R, Druker B, Snead J, MacPartlin M, O'Brien S, Melo J, Lange T, Harrington C, Deininger M

Publication type: Article

Publication status: Published

Journal: Blood

Year: 2010

Volume: 115

Issue: 2

Pages: 315-325

Print publication date: 14/01/2010

ISSN (print): 0006-4971

ISSN (electronic): 1528-0020

Publisher: American Society of Hematology


DOI: 10.1182/blood-2009-03-210732

PubMed id: 19837975


Altmetrics provided by Altmetric


Funder referenceFunder name
Leukemia & Lymphoma Society
National Heart, Lung, and Blood Institute Investigators
Scholar in Clinical Research of the Leukemia & Lymphoma Society
HL082978-01National Heart, Lung, and Blood Institute
HL72321National Heart, Lung, and Blood Institute